menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    AGC Biologics Recognized For Excellence In CDMO Services

    BUSINESSWIRE

    AGC Biologics to Support Adaptimmune’s Solid Tumor Cell Therapy

    CONTRACTPHARMA

    Genenta, AGC Biologics Strengthen Cell Therapy Manufacturing Pact

    CONTRACTPHARMA

    AGC Bio embarks on turnaround strategy under new CEO

    FIERCE PHARMA

    AGC Biologics Appoints Alberto Santagostino as CEO

    ACCESSWIRE

    AGC Biologics Achieves Approval for 2024 BLA

    ACCESSWIRE

    AGC Biologics Begins New Copenhagen Manufacturing Building

    ACCESSWIRE

    AGC Biologics Strengthens Portfolio With Latest FDA Approval

    ACCESSWIRE

    AGC Bio lays off staffers, sidelines Colorado plant

    FIERCE PHARMA

    AGC and Medinet sign agreement for cell therapy CDMO business

    INDIANPHARMAPOST

    AGC Biologics Gains FDA Approval For Copenhagen Facility

    ACCESSWIRE

    NEC Bio And AGC Biologics To Manufacture Cancer Vaccines

    ACCESSWIRE

    Essential Pharma Signs Strategic Agreement with AGC Biologics

    CONTRACT PHARMA

    AGC Biologics: Doubles Copenhagen Bioreactor Capacity After Expansion

    ACCESSWIRE

    AGC, BioConnection Partner On End-To-End Biopharma Offering

    GLOBENEWSWIRE

    AGC Biologics, BioConnection forge partnership to be an alternative to WuXi

    ENDPTS

    AGC plots around 100 layoffs amid tough business environment

    FIERCE PHARMA

    AGC Biologics hit with 483 for poor discrepancy investigation practices, quality control issues at Washington site

    ENDPTS

    FDA Issues Form 483 to AGC Biologics

    FDA

    AGC Biologics to build new government-funded $350M Japanese facility

    ENDPTS

    AGC Biologics Milan Receives Special Award Mention by Confindustria

    BUSINESSWIRE

    AGC Biologics Signs TCR-T Cell Services Agreement to Support Medigene’s Product

    BUSINESSWIRE

    AGC Biologics Inks TCR-T Cell Services Agreement with Medigene

    CONTRACT PHARMA

    AGC Biologics Completes pDNA and mRNA Line Expansion in Heidelberg

    BUSINESSWIRE

    AGC Biologics Offers Guaranteed Delivery of at least 1e11 TU of LVV Material

    BUSINESSWIRE

    AGC Biologics Expands Cell Therapy Suites at Longmont ATMP Campus

    BUSINESSWIRE

    AGC beefs up Colorado cell and gene therapy production facility

    FIERCE PHARMA

    AGC Biologics Partners with Asahi Kasei Pharma on Clinical Antibody Project

    BUSINESSWIRE

    AGC finishes expansion of gene therapy facility in Italy

    FIERCE PHARMA

    AGC Biologics Introduces AGCellerate

    BUSINESSWIRE

    AGC Biologics Launches BravoAAV™ and ProntoLVV™ Platforms

    BUSINESSWIRE

    AGC Biologics Received Bioprocessing Excellence Award in Japan

    BUSINESSWIRE

    AGC Biologics Signs Exosome Agreement with The Jikei University in Japan

    BUSINESSWIRE

    AGC Biologics Copenhagen named Børsen Gazelle company for 2022

    PRESS RELEASE

    Genenta and AGC Biologics Enter Development and Manufacturing Service Agreement

    GLOBENEWSWIRE

    AGC Supports Production of Provention Bio’s Type 1 Diabetes Therapy, TZIELD

    BUSINESSWIRE

    AGC Biologics, Gore Partner on Purification & Mfg. Services for Antibodies

    CONTRACTPHARMA

    AGC Biologics Honored for Innovations in Cell Line Development

    PRESS RELEASE

    AGC Biologics and Evax Partner to Advance Equine Allergy Vaccine Candidate

    GLOBENEWSWIRE

    AGC and RoosterBio partner for cell and exosome therapy manufacturing

    PHARMACEUTICAL-TECHNOLOGY

    AGC Biologics Supports Altheia Science’s Gene Therapy Programs

    CONTRACTPHARMA

    AGC Biologics Named Manufacturing Company of the Year by American

    PRESS RELEASE

    AGC Biologics Expands Cell and Gene Therapy CDMO Capacity at its U.S. site

    AGC

    AGC Biologics Provides Aid to Ukraine

    PRESS RELEASE

    AGC to Expand Synthetic Pharmaceutical Production Base in Spain

    PRNEWSWIRE

    AGC to use recently-expanded Germany site for peanut allergy drug trials

    ENDPTS

    Allergy Selects AGC Biologics to Manufacture Peanut Allergy Vaccine Candidate

    PRESS RELEASE

    AGC Biologics Supports BioNTech Omicron-based Vaccine Candidate with pDNA

    PRESS RELEASE

    AGC Biologics Names Regina Choi-Rivera General Manager of Boulder Facility

    PRESS RELEASE

    AGC Biologics Appoints Jean-Baptiste Agnus as CBO

    CONTRACTPHARMA

    AGC unveils German expansion plans

    ENDPTS

    AGC Biologics expands pDNA and mRNA manufacturing capacity

    BIOSPECTRUM ASIA

    AGC Biologics Breaks Ground on New Facility

    CONTRACT PHARMA

    Often-passed plant in Colorado has a new owner, who`s already operating nearby

    ENDPTS

    AGC is picking up a second commercial plant in CO

    FIERCEPHARMA

    AGC Biologics to Acquire Novartis Facility in Longmont, CO

    CONTRACTPHARMA

    AGC is picking up a second commercial plant in CO

    FIERCEPHARMA

    Chemomab and AGC Biologics Partner to Manufacture CM-101 for Phase II/III

    CONTRACTPHARMA

    AGC Biologics Inks Supply Deal for COVID-19 Vaccine

    CONTRACT PHARMA

    AGC adds major Covid-19 vaccine maker to the client list with BioNTech pact

    ENDPTS

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.